Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088231 · ClinicalTrials.gov registry record · Phase 1
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00088231: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00088231 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088231, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.
Primary Outcome
Time to response is defined as the period of time from the date of first study drug administration until the first objective documentation of response.
Interventions
- DRUG Imatinib Mesylate (Gleevec)
- DRUG PTK 787 (vatalanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00088231 record still lists
NCT00088231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate (Gleevec) is the first listed.
NCT00088231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088231 about?
NCT00088231 is a clinical study titled "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP". The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Anothe...
What is the current status of trial NCT00088231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00088231?
The interventions under investigation include: Imatinib Mesylate (Gleevec) (DRUG), PTK 787 (vatalanib) (DRUG).
Who is sponsoring clinical trial NCT00088231?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088231's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia